Association between renin–angiotensin system inhibitors and COVID-19 complications

202052 citationsJournal Articlebronze Open Access

Authors

Sophie Liabeuf · Centre Hospitalier Universitaire Amiens-Picardie

Julien Moragny · Centre Hospitalier Universitaire Amiens-Picardie

Youssef Bennis · Centre Hospitalier Universitaire Amiens-Picardie

Benjamin Batteux · Centre Hospitalier Universitaire Amiens-Picardie

Étienne Brochot · Agents infectieux, résistance et chimiothérapie

Jean Luc Schmit · Centre Hospitalier Universitaire Amiens-Picardie

Abstract

We highlighted a potential safety signal for RASIs, the long-term use of which was independently associated with a higher risk of severe COVID-19 and a poor outcome. Due to the widespread use of this important drug class, formal proof based on clinical trials is needed to better understand the association between RASIs and complications of COVID-19.

Topics & Keywords

COVID-19 Clinical Research Studies Long-Term Effects of COVID-19 SARS-CoV-2 and COVID-19 Research

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: European Heart Journal - Cardiovascular Pharmacotherapy

Volume 7, Issue 5, pp. 426-434

DOI: 10.1093/ehjcvp/pvaa062

Field-Weighted Citation Impact: 1.24